Study how timing between Ebola shots affects the immune response
Part of Infections clinical trials.
This Phase 2 study compares Ebola vaccine immune responses when one Ebola treatment (Inmazeb) is given, then a vaccine (Ervebo) is given later. The goal is to see how the delay in timing changes your body’s immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can stay in the study for the full follow-up time
- You agree to participate and sign consent
- You agree not to join another clinical study during this trial’s follow-up
- You have no past Ebola virus disease history
- You have not had an Ebola vaccine before and have not received Ebola antibody treatment before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This trial tests an experimental treatment to prevent Ebola infection in people who have had close contact with someone infected with Ebola within the last 5 days. If you've been in a high-risk situation, joining this trial could help protect you and others.
This study tests whether it is safe and effective to give an Ebola vaccine at the same time as a COVID-19 booster shot. It may help find a way to protect against both diseases with fewer clinic visits.
This trial tests an Ebola vaccine in healthy people from local communities to see how it works and how safe it is. You may be able to join if you meet age, health, and vaccination/medication rules and can follow pregnancy-prevention and consent requirements.
This Phase 2 study tests whether a VEE (Venezuelan equine encephalitis) booster vaccine is safe and helps your immune system respond in adults. It is for people previously vaccinated with VEE TC-83 who currently have low immune protection.
This study tests a new mRNA vaccine (mRNA-1469) to prevent Ebola-Bundibugyo virus disease. It is for healthy adults to see if the vaccine is safe and produces an immune response.
Hear when a new Ebola Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.